Regencell Bioscience Holdings Limited · NASDAQ:RGC
Regencell Bioscience — IPO Roadshow (June 2021)
22 slides from Regencell Bioscience's IPO roadshow presentation, Jun 30, 2021
Slide 1: Regencell Bioscience Corporate Presentation June 2021
Regencell Bioscience To improve the lives of ADHD and ASD patients, their families and caregivers & become a market leader for the best treatment of ADHD and ASD Corporate Presentation June 2021 Issuer Free Writing Prospectus dated June 28, 2021 Filed Pursuant to Rule 433 of the Securities Act of 19
Slide 2: Free Writing Prospectus Statement
Regencell Bioscience Holdings Limited | 2 Free Writing Prospectus Statement ▪ This free writing prospectus relates to the proposed initial public offering of ordinary shares of Regencell Bioscience Holdings Limited (the “Company”), which are being registered on a registration statement and should be
Slide 3: Forward Looking Statements
Regencell Bioscience Holdings Limited | 3 Forward Looking Statements All statements in this presentation, other than those relating to historical facts, are "forward - looking statements . ” These forward - looking statements may include, but are not limited to, statements relating to our objectives
Slide 4: Offering Summary
Regencell Bioscience Holdings Limited | 4 ISSUER: Regencell Bioscience Holdings Limited PROPOSED EXCHANGE // SYMBOL: Nasdaq Capital Market // RGC OFFERING TYPE : Initial Public Offering OFFERING SIZE: Approximately $ 21.9 million (excluding 15% over - allotment option) SECURITIES OFFERED: Ordinary s
Slide 5: About Us
Regencell Bioscience Holdings Limited | 5 About Us • We are an early - stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, with initial products in development for
Slide 6: Investment Highlights
Regencell Bioscience Holdings Limited | 6 Investment Highlights • Addressing large neurocognitive disorders markets with unmet needs • Lead products are proprietary TCM formulae based on over 30 years of Mr . Sik - Kee Au's clinical experience • Promising results from our first research study • Clea
Slide 7: Large Markets with Unmet Needs
Regencell Bioscience Holdings Limited | 7 Large Markets with Unmet Needs Main Symptoms ADHD Lack of attention, hyperactive, impulsive behavior, excessive physical movement and little or no sense of danger . Some may also have signs of anxiety, oppositional defiant and conduct disorder, depression an
Slide 8: ADHD Common Medications
Regencell Bioscience Holdings Limited | 8 ADHD Common Medications • Stimulants : H elp focus thoughts and ignore distractions . Work for 70 % to 80 % of people . Used to treat moderate and severe ADHD ( 1 ) • Non - stimulants : In cases where stimulants don’t work or cause unpleasant side effects, n
Slide 9: Growing Needs for Safe and Effective Treatments
Regencell Bioscience Holdings Limited | 9 Source: Persistence Market Research Analysis 2020 Report 21.5 22.5 23.5 24.7 25.9 27.3 28.6 30.1 31.6 33.1 34.7 36.5 3.4 3.6 3.8 4.1 4.3 4.6 4.9 5.1 5.4 5.8 6.1 6.4 24.9 26.1 27.4 28.7 30.2 31.8 33.5 35.2 37.0 38.9 40.8 42.9 - 10.0 20.0 30.0 40.0 50.0 Global
Slide 10: Our Proprietary TCM Formulae
Regencell Bioscience Holdings Limited | 10 Our Proprietary TCM Formulae • Sik - Kee Au TCM Brain Theory Я explains why a healthy brain is essential in restoring the body’s systems to normal from disorders and illnesses such as ADHD and ASD • According to the Sik - Kee Au TCM Brain Theory Я , the blo
Slide 11: Our TCM Formulae Candidates
Regencell Bioscience Holdings Limited | 11 Our TCM Formulae Candidates • One theory : all formulae are developed based on Sik - Kee Au TCM Brain Theory Я • Two components in each TCM formula candidate : standard base formula + fixed adjusted formula • Three liquid - based TCM formulae candidates (mi
Slide 12: Our First Research Study
Regencell Bioscience Holdings Limited | 12 Our First Research Study • C ommenced in November 2018 ( 6 patients) and March 2019 ( 1 patient) • Seven patients, between five and eleven years old, who were clinically diagnosed with ADHD or ASD by healthcare professionals • Designed with a small sample s
Slide 13: Our First Research Study Results
Regencell Bioscience Holdings Limited | 13 Our First Research Study Results Assessment Tools Ranges of Change Mean Change Median Change ATEC - 19% to - 67% - 37% - 35% GARS 1% to - 59% - 33% - 34% VADRS - 8% to - 49% - 30% - 32% SNAP - IV - 26 - 5% to - 44% - 28% - 33% 1. Patients were treated by th
Slide 14: Our Planned Second Research Study
Regencell Bioscience Holdings Limited | 14 Our Planned Second Research Study Objective • Validate efficacy of the three standardized TCM formulae candidates for mild, moderate and severe conditions • Provide foundation for proprietary Chinese medicine (“pCm”) registration Study Design • Sample size:
Slide 15: • We estimate that it will take us approximately four years to commercialize our
Regencell Bioscience Holdings Limited | 15 • We estimate that it will take us approximately four years to commercialize our standardized TCM formulae candidates in Hong Kong : • Approximately one year to complete our second research study, including enrollment of qualified patients for treatment by
Slide 16: Development Strategy and Timeline
Regencell Bioscience Holdings Limited | 16 Development Strategy and Timeline Note: The projected timeline above is what we aim to achieve but there is no guarantee that any of the listed milestones will be me t i n the time noted or at all. Disclaimer : The information contained in this document is
Slide 17: Exclusivity and Intellectual Property Strategy
Regencell Bioscience Holdings Limited | 17 Exclusivity and Intellectual Property Strategy P roprietary TCM F ormulae P roprietary Production Processes and Equipment Brand and Marketing IP Protection Strategies • Exclusive rights and ownership of all the TCM Practitioner’s formulae and their IP right
Slide 18: Management Team
Regencell Bioscience Holdings Limited | 18 ▪ Established Regencell in 2014 ▪ Founding partner of one of California’s largest group of property investors which partners with the leading pension and private equity funds with assets over US $ 250 billion ▪ Bachelor of Science degree from the Haas Schoo
Slide 19: Independent Directors
Regencell Bioscience Holdings Limited | 19 Independent Directors ▪ Over 20 years of retail and brand management experience ▪ 18 - year at the Dairy Farm Company Limited, a leading pan - Asian retailer, responsible for product development, brand building, customer loyalty, and sales and profitability
Slide 20: Use of Proceeds
Regencell Bioscience Holdings Limited | 20 Use of Proceeds • We plan to use the estimated IPO net proceeds of $19.3M (if no over - allotment is exercised) for the following purposes, with an estimated total of $29M needed to attain approval of our pCm formulae in Hong Kong: (1) Estimated The foregoi
Slide 21: Commitments from Strategic Partner and Chairman
Regencell Bioscience Holdings Limited | 21 ▪ Commitments from our strategic partner, Mr . Sik - Kee Au • Dedicated to treat people afflicted with incurable illnesses, disorders and degeneration • Inventor of the TCM formulae that form the basis for our TCM formulae products for ADHD and ASD • Contri
Slide 22: Thank You
Thank You
Regencell Bioscience Holdings — IPO Roadshow (June 2021) on 6ix